Back to top
more

Applied Genetic Technologies Corporation (AGTC)

(Delayed Data from NSDQ)

$4.30 USD

4.30
10,505

-0.04 (-0.92%)

Updated May 3, 2019 04:13 PM ET

After-Market: $4.40 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Applied Genetic Technologies (AGTC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.

Applied Genetic Technologies (AGTC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -17.65% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Applied Genetic Technologies (AGTC) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Applied Genetic Technologies (AGTC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Applied Genetic Technologies (AGTC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AGTC) Outperforming Other Medical Stocks This Year?

Zealand Announces Dosing Initiation in Type 2 Diabetes Study

by Zacks Equity Research

Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.

Applied Genetic (AGTC) Soars: Stock Adds 6.1% in Session

by Zacks Equity Research

Applied Genetic (AGTC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Dynavax's Partner Doses First Patient in Coronavirus Study

by Zacks Equity Research

Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.

Reata Surges on $350 Million Investment Deal With Blackstone

by Zacks Equity Research

Reata (RETA) announces a royalty and equity investment deal with Blackstone Group, which will support development of its lead pipeline candidate, bardoxolone methyl, in chronic kidney diseases.

Is Applied Genetic Technologies (AGTC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AGTC) Outperforming Other Medical Stocks This Year?

Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B

by Zacks Equity Research

Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.

Mersana Stock Spikes on Interim Data on Cancer Candidate

by Zacks Equity Research

Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.

Why Applied Genetic Technologies (AGTC) Stock Might be a Great Pick

by Zacks Equity Research

The Applied Genetic Technologies (AGTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Applied Genetic Technologies (AGTC) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Is Applied Genetic Technologies (AGTC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (AGTC) Outperforming Other Medical Stocks This Year?

Applied Genetic Technologies (AGTC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 9.09% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Applied Genetic Technologies' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Applied Genetic Technologies.

Earnings Preview: Applied Genetic Technologies (AGTC) Q3 Earnings Expected to Decline

by Zacks Equity Research

Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Applied Genetic Technologies' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Applied Genetic Technologies.

All You Need to Know About Applied Genetic Technologies (AGTC) Rating Upgrade to Buy

by Zacks Equity Research

Applied Genetic Technologies (AGTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Applied Genetic Stock Up on Favorable Eye Therapy Study Data

by Zacks Equity Research

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

Company News for Jan 10, 2020

by Zacks Equity Research

Companies In The News Are:

Implied Volatility Surging for Applied Genetic Technologies (AGTC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.

Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -10.34% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Applied Genetic Technologies (AGTC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -13.73% and -42.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?